RM LAW, P.C. is investigating potential claims against the board of directors of AveXis, Inc. (“AveXis” or the “Company”) (NASDAQ: AVXS) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell the Company to Novartis in a transaction valued at approximately $8.7 billion.
If you own shares of AveXis and would like to learn more about this class action or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here. You may also email Mr. Maniskas at email@example.com.
Under the terms of the agreement, shareholders of AveXis will receive $218.00 in cash for each share of AveXis common stock.
Our investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of AveXis for not acting in the Company’s shareholders’ best interests in connection with the sale process.